|
Date |
|
Title |
|
January 18, 2010
|
|
|
|
September 30, 2009
|
|
|
|
September 21, 2009
|
|
|
|
August 27, 2009
|
|
|
|
June 16, 2009
|
|
|
|
April 08, 2009
|
|
|
|
February 10, 2009
|
|
|
|
January 30, 2009
|
|
|
|
December 17, 2008
|
|
|
|
December 4, 2008
|
|
|
|
September 2, 2008
|
|
|
|
July 30, 2008
|
|
|
|
June 24, 2008
|
|
|
|
June 3, 2008
|
|
Anavex further strengthens
Board of Directors |
|
May 21, 2008
|
|
Anavex Announces
Appointment of Oncology Specialist
to Board of Directors |
|
March 10, 2008
|
|
Anavex 7-1037 reduces
rate of cancer tumor growth 69%
in preclinical studies, compared to currently marketed
drug Dacarbazine showing no measurable activity |
|
January 22, 2008
|
|
ANAVEX outlines corporate
milestones, drug advancement
plans for 2008 |
|
December 17, 2007
|
|
Anavex strengthens
Board of Directors |
|
December 11, 2007
|
|
ANAVEX 7-1037 demonstrates
chemotherapeutic potential without toxic side effects for the treatment of colorectal
cancer, other types of solid tumors |
|
December 6, 2007
|
|
ANAVEX advances drug
candidates for treatment of epilepsy |
|
November 28, 2007
|
|
Anavex advances drug
candidate for treatment of Alzheimer’s disease |
|
November 2, 2007
|
|
Anavex Life Sciences
engages Primoris Group to provide
investor relations services |
|
June 5, 2007
|
|
Annual General Meeting
of the shareholders of Anavex
Life Sciences Corp. |
|
May 23, 2007
|
|
Preclinical Data
of ANAVEX 1-41 and ANAVEX 2-73,
Show Highly Potent Anti-Amnesic and Neuroprotective
Activity Against Amyloid Beta (25-35) Peptide Toxicity
in Alzheimer’s Disease (AD) Animal Models. |
|
April 16, 2007
|
|
Dr. Jean Jacques
Bourguignon Joins Anavex Life Sciences
Corp. Scientific Team
|
|
April 2, 2007
|
|
Anavex Life Sciences
Corp. Announces Research Agreement With University of Paris 5-Rene Descartes
|
|
February 12, 2007
|
|
Anavex Life Sciences
Corp. Announces Its Preclinical
Pipeline of Novel Oncology Therapies
|
|
February 7, 2007
|
|
Anavex Life Sciences
Corp. Appoints VP Business Development and VP Strategic Planning |
|
February 1, 2007
|
|
Anavex Life Sciences
Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics |
|
January 31, 2007
|
|
Anavex Life Sciences
Corp. Acquires a Portfolio of Patents
and Appoints Dr. Alexandre Vamvakides as CSO and Director |
|
January 25, 2007
|
|
Anavex Life Sciences
Corp.: Appointment of CEO and Director |
